Dupilumab is a first-in-class biologic utilised in the treatment of multiple atopic diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. Although dupilumab is exceptionally effective in treating atopic dermatitis, a range of ocular side effects associated with dupilumab usage have been reported in these patients.

A collaborative effort by clinicians from Australia and Singapore sought to explore and summarise the current evidence surrounding ocular manifestations of dupilumab-associated disease and their management to provide an overview of this unique disease entity.

Recommendations on screening, monitoring and management of patients with dupilumab associated ocular side-effects have also been made in this paper.

For full paper, see here: https://www.surveyophthalmol.com/article/S0039-6257(22)00030-3/fulltext